ES2345274T3 - Construcciones inmunogenicas. - Google Patents

Construcciones inmunogenicas. Download PDF

Info

Publication number
ES2345274T3
ES2345274T3 ES06765201T ES06765201T ES2345274T3 ES 2345274 T3 ES2345274 T3 ES 2345274T3 ES 06765201 T ES06765201 T ES 06765201T ES 06765201 T ES06765201 T ES 06765201T ES 2345274 T3 ES2345274 T3 ES 2345274T3
Authority
ES
Spain
Prior art keywords
seq
polypeptide
baselineskip
sequence
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06765201T
Other languages
English (en)
Spanish (es)
Inventor
John Hermon-Taylor
Timothy John Bull
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HAV Vaccines Ltd
Original Assignee
HAV Vaccines Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HAV Vaccines Ltd filed Critical HAV Vaccines Ltd
Application granted granted Critical
Publication of ES2345274T3 publication Critical patent/ES2345274T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES06765201T 2005-08-09 2006-08-03 Construcciones inmunogenicas. Expired - Lifetime ES2345274T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70659405P 2005-08-09 2005-08-09
US706594P 2005-08-09

Publications (1)

Publication Number Publication Date
ES2345274T3 true ES2345274T3 (es) 2010-09-20

Family

ID=36992793

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06765201T Expired - Lifetime ES2345274T3 (es) 2005-08-09 2006-08-03 Construcciones inmunogenicas.

Country Status (11)

Country Link
US (2) US7892566B2 (enExample)
EP (1) EP1913020B1 (enExample)
JP (1) JP5244593B2 (enExample)
AT (1) ATE466876T1 (enExample)
AU (1) AU2006277828B2 (enExample)
CA (1) CA2617506C (enExample)
DE (1) DE602006014164D1 (enExample)
DK (1) DK1913020T3 (enExample)
ES (1) ES2345274T3 (enExample)
NZ (1) NZ565695A (enExample)
WO (1) WO2007017635A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9806093D0 (en) * 1998-03-20 1998-05-20 Taylor John Hermon Diagnostics and vaccines for mycobacterial infections of animals and humans
ATE466876T1 (de) 2005-08-09 2010-05-15 Hav Vaccines Ltd Immunogene konstrukte
GB201700487D0 (en) * 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic
CN109125740B (zh) * 2017-06-28 2022-04-05 成都威斯克生物医药有限公司 一种新型的肿瘤疫苗及其用途
GB201811382D0 (en) 2018-07-11 2018-08-29 Taylor John Hermon Vaccine
WO2026041756A1 (en) * 2024-08-21 2026-02-26 Hav Vaccines Limited Treatment of crohn's disease by mycobacterium avium subsp. paratuberculosis agent

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8709803D0 (en) 1987-04-24 1987-05-28 Mcfadden J J Treatment of crohn's disease &c
US5225324A (en) 1987-04-24 1993-07-06 Bioscience International, Inc. Diagnostics for mycobacteria in public health, medical, and veterinary practice
FR2682967B1 (fr) 1991-10-25 1994-01-14 Pasteur Institut Nouveau promoteur de m. paratuberculosis. son utilisation pour le clonage et l'expression de sequences nucleotidiques.
EP0805863A2 (en) * 1994-12-20 1997-11-12 New Zealand Pastoral Agriculture Research Institute Limited METHODS AND COMPOSITIONS FOR DETECTING AND TREATING MYCOBACTERIAL INFECTIONS USING AN ahpCF OPERON
GB9526178D0 (en) 1995-12-21 1996-02-21 Taylor John Hermon Novel polynuceotides and polypeptides in pathogenic mycobacteria and their use as diagnostics,vaccines and targets for chemotherapy
GB9806093D0 (en) * 1998-03-20 1998-05-20 Taylor John Hermon Diagnostics and vaccines for mycobacterial infections of animals and humans
US7393540B2 (en) * 2001-07-04 2008-07-01 Health Protection Agency Mycobacterial antigens expressed during latency
CN102294023A (zh) * 2001-07-26 2011-12-28 奥塔戈创新公司 抗原组合物
CA2473226A1 (en) * 2002-01-11 2003-07-17 Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. Diagnostics and vaccines for mycrobacterium paratuberculosis infections
ATE466876T1 (de) 2005-08-09 2010-05-15 Hav Vaccines Ltd Immunogene konstrukte

Also Published As

Publication number Publication date
US20090203593A1 (en) 2009-08-13
WO2007017635A1 (en) 2007-02-15
US20110129502A1 (en) 2011-06-02
ATE466876T1 (de) 2010-05-15
JP2009504149A (ja) 2009-02-05
JP5244593B2 (ja) 2013-07-24
AU2006277828A1 (en) 2007-02-15
EP1913020A1 (en) 2008-04-23
EP1913020B1 (en) 2010-05-05
DK1913020T3 (da) 2010-08-09
AU2006277828B2 (en) 2012-02-02
CA2617506C (en) 2015-02-03
DE602006014164D1 (de) 2010-06-17
US7892566B2 (en) 2011-02-22
NZ565695A (en) 2011-01-28
US8147850B2 (en) 2012-04-03
CA2617506A1 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
ES2230596T3 (es) Mezcla de vectores de vaccinia recombinantes como vacunas poligueur contra el vih.
ES2395305T3 (es) Antígeno de fusión utilizado como vacuna
KR20210092762A (ko) 아프리카 돼지 열병 바이러스에 대한 면역원성 조성물
Rothel et al. Sequential nucleic acid and recombinant adenovirus vaccination induces host‐protective immune responses against Taenia ovis infection in sheep
Jain et al. Evaluation of immunogenicity and protective efficacy of a plasmid DNA vaccine encoding ribosomal protein L9 of Brucella abortus in BALB/c mice
BR112014031327B1 (pt) Moléculas de ácido nucleico para o tratamento de alergias
Chambers et al. Vaccination of mice and cattle with plasmid DNA encoding the Mycobacterium bovis antigen MPB83
CA3233697A1 (en) Recombinant fusion protein derived from hr region of s2 protein of sars-cov-2 and application of recombinant fusion protein
Zhu et al. Enhancement of DNA vaccine potency against herpes simplex virus 1 by co-administration of an interleukin-18 expression plasmid as a genetic adjuvant
US6492145B1 (en) Vaccine against mycobacterial infections
EA027981B1 (ru) Вакцина против пневмонии, вызываемой streptococcus pneumoniae, на основе гибридного белка
US8147850B2 (en) Immunogenic constructs
Roque-Resendiz et al. MVA ROP2 vaccinia virus recombinant as a vaccine candidate for toxoplasmosis
CN114272364B (zh) 一种结核分枝杆菌串联dna疫苗w541及其制备方法与应用
Mingxiao et al. Immunogenicity of plasmids encoding P12A and 3C of FMDV and swine IL-18
JP2024153666A (ja) パラ結核症のための免疫原性組成物
Martin et al. The combination of plasmid interleukin‐12 with a single DNA vaccine is more effective than Mycobacterium bovis (bacille Calmette–Guèrin) in protecting against systemic Mycobacterim avium infection
Kim et al. The immune response induced by DNA vaccine expressing nfa1 gene against Naegleria fowleri
Khandelia et al. An overview of the BCG vaccine and its future scope
KR101955365B1 (ko) 신규한 클로스트리듐 디피실(Clostridium Difficile) DNA 백신
KR101603838B1 (ko) 브루셀라 균주 유래 ｎｄｋ 재조합 항원을 이용한 브루셀라 감염증 예방 방법
ES2546301T3 (es) Composición que contiene Leishmania Lip2a
Choi et al. Prevention of encephalomyocarditis virus-induced diabetes by live recombinant Mycobacterium bovis bacillus Calmette-Guérin in susceptible mice.
CN115427433A (zh) 保护性葡萄球菌外毒素疫苗
CN108794636A (zh) 一种表位多肽串联混合物在抗立氏立克次体的免疫保护中的应用